Have you lost money investing in TG Therapeutics? If yes, please visit us TG Therapeutics, Inc. Shareholder Class Action or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a nationally recognized investor rights law firm, is reminding investors of the deadline for filing a motion by lead plaintiff in a securities class action lawsuit filed on behalf of investors who have bought or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York alleging violations of the Securities Exchange Act of 1934.

TG Therapeutics is a commercial-stage biopharmaceutical company. Therapeutic product candidates include ubituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (“CLL”) and relapsing forms of multiple sclerosis; and umbralisib or UKONIQ, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma and follicular lymphoma.

In January 2020, TG Therapeutics initiated a rolling New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”) to accelerate approval of umbralisib as a treatment for patients with previously treated marginal zones -Lymphoma (“MZL”) and follicular lymphoma (“FL”) (the “Umbralisib MZL/FL NDA”).

In December 2020, TG Therapeutics initiated a rolling submission of a Biologics License Application (“BLA”) to the FDA for ubituximab in combination with umbralisib (collectively “U2”) as a treatment for patients with CLL (the “U2 BLA”). ).

In May 2021, TG Therapeutics filed a supplemental New Drug…